The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary edema, noncardiogenic (NCPE)
Can be triggered by blood transfusion
Publications
A prospective study of pulmonary function in patients receiving mitomycin.
Chest. 1996;109(4):939-44
Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome.
Cancer treatment reports. 1983;67(5):429-34
Mitomycin C associated hemolytic uremic syndrome.
Pathology. 1987;19(1):58-61
A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma.
Cancer. 1986;58(7):1428-36
Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazze L, Schein PS
Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989;7(6):781-9
[A case from practice (238). Mitomycin- and vindesine-induced interstitial pulmonary edema--bronchus carcinoma of the left upper lobe--chronic obstructive lung disease].
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis. 1992;81(12):382-4